Rare CDK12 germline mutation linked to hereditary aggressive prostate cancer in five-family study

Researchers have identified a rare inherited CDK12 variant in five families, with all identified carriers developing metastatic prostate cancer, raising questions about the scope of hereditary prostate cancer genetics.

Published · AI-drafted summary based on 1 public source
Illustration for oncology story
Illustrative image — not from the source article.
Share

A study reported by ScienceDaily has described a rare germline mutation in the CDK12 gene associated with hereditary aggressive prostate cancer. All five carriers identified across the studied families developed metastatic disease, with onset ranging from 44 to 62 years of age.

CDK12 encodes cyclin-dependent kinase 12, a protein involved in DNA damage repair and transcriptional regulation. Somatic CDK12 alterations have previously been characterised in prostate tumours, particularly in association with a genomic instability phenotype and tandem duplications, but germline inheritance of pathogenic CDK12 variants has received comparatively little attention in hereditary prostate cancer genetics.

The findings are early-stage — five families is a small ascertainment — and the study, as reported by ScienceDaily, does not appear to have been published in a peer-reviewed journal at the time of writing. No primary paper or institution was named in available reporting, which limits independent verification. These caveats notwithstanding, the observation that all identified carriers developed metastatic disease is biologically noteworthy and may prompt researchers to look more systematically at CDK12 in hereditary prostate cancer cohorts.

For genetics professionals and oncologists with an interest in hereditary prostate cancer, this finding adds to a growing list of moderate- and high-penetrance genes beyond BRCA1, BRCA2, and HOXB13 that warrant attention in research settings. It does not at present alter any published clinical guidelines.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

Scientists have reported finding a rare inherited change in a gene called CDK12 in five families. All five family members who carried this gene change went on to develop an aggressive, advanced form of prostate cancer.

Genes carry instructions that help cells repair damage to their DNA. CDK12 is one such gene. Researchers already knew that changes in this gene sometimes appear in prostate tumours, but this study suggests the change can sometimes be inherited — passed down through families — rather than arising only in cancer cells.

This research is very early. Only five families were studied, and the findings have not yet been confirmed in a large, peer-reviewed study. It does not change current medical guidance about prostate cancer screening or genetic testing.

This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source ScienceDaily · 2026-11-19
    Scientists discover a hidden hereditary form of aggressive prostate cancer

Tags

cdk12 hereditary-prostate-cancer germline-variants metastatic-cancer oncology hereditary-cancer dna-repair
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List